Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026GlobeNewsWire • 02/10/26
CeriBell, Inc. (CBLL) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke DetectionZacks Investment Research • 01/06/26
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring SolutionGlobeNewsWire • 01/05/26
CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring SolutionZacks Investment Research • 12/12/25
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring SolutionGlobeNewsWire • 12/09/25
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for NeonatesGlobeNewsWire • 11/24/25
Ceribell to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewsWire • 11/19/25
CeriBell, Inc. (CBLL) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/28/25
Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in DelawareGlobeNewsWire • 07/07/25
Ceribell to Participate in the William Blair 45th Annual Growth Stock ConferenceGlobeNewsWire • 05/20/25